The DOI matches its Crossref record; 154 of the 154 references it cites were found in a registry or an index.
COVID-19: Discovery, diagnostics and drug development
Open accessAbstract
Coronavirus disease 2019 (COVID-19) started as an epidemic in Wuhan in 2019, and has since become a pandemic. Groups from China identified and sequenced the virus responsible for COVID-19, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and determined that it was a novel coronavirus sharing high sequence identity with bat- and pangolin-derived SARS-like coronaviruses, suggesting a zoonotic origin. SARS-CoV-2 is a member of the Coronaviridae family of enveloped, positive-sense, single-stranded RNA viruses that infect a broad range of vertebrates. The rapid release of the sequence of the virus has enabled the development of diagnostic tools. Additionally, serological tests can now identify individuals who have been infected. SARS-CoV-2 infection is associated with a fatality rate of around 1–3%, which is commonly linked to the development of acute respiratory distress syndrome (ARDS), likely resulting from uncontrolled immune activation, the so called “cytokine storm”. Risk factors for mortality include advanced age, obesity, diabetes, and hypertension. Drug repurposing has been used to rapidly identify potential treatments for COVID-19, which could move quickly to phase III. Better knowledge of the virus and its enzymes will aid the development of more potent and specific direct-acting antivirals. In the long term, a vaccine to prevent infection is crucial; however, even if successful, it might not be available before 2021-22. To date, except for intravenous remdesivir and dexamethasone, which have modest effects in moderate to severe COVID-19, no strong clinical evidence supports the efficacy of any other drugs against SARS-CoV-2. The aim of this review is to provide insights on the discovery of SARS-CoV-2, its virology, diagnostic tools, and the ongoing drug discovery effort.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Cai, Q., Yang, M., Liu, D., Chen, J., Shu, D., Xia, J., Liao, X., Gu, Y., Cai, Q., Yang, Y., et al. (2020) · Engineering · doi:10.1016/j.eng.2020.03.007 · Cited by 1,357
RetractedClinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report
Horby, P., Lim, W. S., Emberson, J., Mafham, M., Bell, J., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., et al. (2020) · doi:10.1101/2020.06.22.20137273 · Cited by 11,475 · cited 1×
“In a controlled, open-label trial of patients hospitalised with COVID-19, patients were randomly assigned to receive oral or intravenous dexamethasone (6 mg once daily) for up to 10 days or to receive SOC alone.(136) In the dexamethasone group, the incidence of death was lower than that in the SOC group among patients…”
MethodAerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1
van Doremalen, N., Bushmaker, T., Morris, D. H., Holbrook, M. G., Gamble, A., Williamson, B. N., Tamin, A., Harcourt, J. L., Thornburg, N. J., Gerber, S. I., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2004973 · Cited by 9,951 · cited 1×
“In accordance with a surface stability study on plastic and different materials, SARS-CoV-2 could remain viable for up to 72 hours.(116) In 1 study, faecal samples remained SARS-CoV-2 positive despite respiratory clearance in 20% of patients.”
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664
Chan, J. F.-W., Yuan, S., Kok, K.-H., To, K. K.-W., Chu, H., Yang, J., Xing, F., Liu, J., Yip, C. C.-Y., Poon, R. W.-S., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30154-9 · Cited by 8,944
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K., Bleicker, T., Brünink, S., Schneider, J., Schmidt, M. L., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.3.2000045 · Cited by 7,344
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19
Ackermann, M., Verleden, S. E., Kuehnel, M., Haverich, A., Welte, T., Laenger, F., Vanstapel, A., Werlein, C., Stark, H., Tzankov, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2015432 · Cited by 5,613
Grasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., Cereda, D., Coluccello, A., Foti, G., Fumagalli, R., et al. (2020) · JAMA · doi:10.1001/jama.2020.5394 · Cited by 5,469 · cited 1×
“In another study of the 1,591 patients infected with SARS-CoV-2 admitted to ICUs in Italy, the median age was 63 years and 82% were male.(82) Among 1,300 patients with available data on respiratory support, 99% needed respiratory support, including 88% who received mechanical ventilation and 11% who received non-invas…”
BackgroundA Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187
The proximal origin of SARS-CoV-2
Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C., & Garry, R. F. (2020) · Nature Medicine · doi:10.1038/s41591-020-0820-9 · Cited by 5,081
Detection of SARS-CoV-2 in Different Types of Clinical Specimens
Wang, W., Xu, Y., Gao, R., Lu, R., Han, K., Wu, G., & Tan, W. (2020) · JAMA · doi:10.1001/jama.2020.3786 · Cited by 5,028
SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients
Zou, L., Ruan, F., Huang, M., Liang, L., Huang, H., Hong, Z., Yu, J., Kang, M., Song, Y., Xia, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2001737 · Cited by 4,810
Clinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · cited 2×
“mRNA-based vaccines contain mRNAs encoding the antigens, which are translated at the host cellular machinery by vaccination.(156) mRNA vaccines have advantages over conventional vaccines, including the absence of genome integration, the improved immune responses, their rapid development, and the production of multimer…”
BackgroundStructure of Mpro from SARS-CoV-2 and discovery of its inhibitors
Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., Zhang, B., Li, X., Zhang, L., Peng, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2223-y · Cited by 4,358
Temporal dynamics in viral shedding and transmissibility of COVID-19
He, X., Lau, E. H. Y., Wu, P., Deng, X., Wang, J., Hao, X., Lau, Y. C., Wong, J. Y., Guan, Y., Tan, X., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0869-5 · Cited by 4,247
Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany
Rothe, C., Schunk, M., Sothmann, P., Bretzel, G., Froeschl, G., Wallrauch, C., Zimmer, T., Thiel, V., Janke, C., Guggemos, W., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2001468 · Cited by 4,144
Structural basis of receptor recognition by SARS-CoV-2
Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31022-9 · Cited by 3,440
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406 · cited 1×
“A preliminary report on an mRNA vaccine against SARS-CoV-2 has been published.(158) The candidate vaccine mRNA-1273 (Moderna) is a lipid nanoparticle–encapsulated, nucleoside-modified mRNA–based vaccine that encodes the SARS-CoV2 spike glycoprotein stabilised in its prefusion conformation.”
BackgroundOu, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15562-9 · Cited by 3,097
To, K. K.-W., Tsang, O. T.-Y., Leung, W.-S., Tam, A. R., Wu, T.-C., Lung, D. C., Yip, C. C.-Y., Cai, J.-P., Chan, J. M.-C., Chik, T. S.-H., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30196-1 · Cited by 3,066
COVID-19 and the cardiovascular system
Zheng, Y.-Y., Ma, Y.-T., Zhang, J.-Y., & Xie, X. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0360-5 · Cited by 2,970
The effect of human mobility and control measures on the COVID-19 epidemic in China
Kraemer, M. U. G., Yang, C.-H., Gutierrez, B., Wu, C.-H., Klein, B., Pigott, D. M., Open COVID-19 Data Working Group, du Plessis, L., Faria, N. R., Li, R., et al. (2020) · Science · doi:10.1126/science.abb4218 · Cited by 2,950
Coronavirus as a possible cause of severe acute respiratory syndrome
Peiris, J., Lai, S., Poon, L., Guan, Y., Yam, L., Lim, W., Nicholls, J., Yee, W., Yan, W., Cheung, M., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13077-2 · Cited by 2,915
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Evidence for gastrointestinal infection of SARS-CoV-2
Xiao, F., Tang, M., Zheng, X., Liu, Y., Li, X., & Shan, H. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.02.055 · Cited by 2,836
CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV)
Chung, M., Bernheim, A., Mei, X., Zhang, N., Huang, M., Zeng, X., Cui, J., Xu, W., Yang, Y., Fayad, Z. A., et al. (2020) · Radiology · doi:10.1148/radiol.2020200230 · Cited by 2,751
Compassionate Use of Remdesivir for Patients with Severe Covid-19
Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., Feldt, T., Green, G., Green, M. L., Lescure, F.-X., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007016 · Cited by 2,737
CRISPR–Cas12-based detection of SARS-CoV-2
Broughton, J. P., Deng, X., Yu, G., Fasching, C. L., Servellita, V., Singh, J., Miao, X., Streithorst, J. A., Granados, A., Sotomayor-Gonzalez, A., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0513-4 · Cited by 2,717
Neurologic features in severe SARS-CoV-2 infection
Helms, J., Kremer, S., Merdji, H., Clere-Jehl, R., Schenck, M., Kummerlen, C., Collange, O., Boulay, C., Fafi-Kremer, S., Ohana, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2008597 · Cited by 2,674
Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection
Bernheim, A., Mei, X., Huang, M., Yang, Y., Fayad, Z. A., Zhang, N., Diao, K., Lin, B., Zhu, X., Li, K., et al. (2020) · Radiology · doi:10.1148/radiol.2020200463 · Cited by 2,655
Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing
Ferretti, L., Wymant, C., Kendall, M., Zhao, L., Nurtay, A., Abeler-Dörner, L., Parker, M., Bonsall, D., & Fraser, C. (2020) · Science · doi:10.1126/science.abb6936 · Cited by 2,512
HCA Lung Biological Network, Sungnak, W., Huang, N., Bécavin, C., Berg, M., Queen, R., Litvinukova, M., Talavera-López, C., Maatz, H., Reichart, D., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0868-6 · Cited by 2,501
Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
COVID-19 and its implications for thrombosis and anticoagulation
Connors, J. M., & Levy, J. H. (2020) · Blood · doi:10.1182/blood.2020006000 · Cited by 2,369
Ziegler, C. G. K., Allon, S. J., Nyquist, S. K., Mbano, I. M., Miao, V. N., Tzouanas, C. N., Cao, Y., Yousif, A. S., Bals, J., Hauser, B. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.035 · Cited by 2,284
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., et al. (2020) · JAMA · doi:10.1001/jama.2020.4783 · Cited by 2,277
Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore
Young, B. E., Ong, S. W. X., Kalimuddin, S., Low, J. G., Tan, S. Y., Loh, J., Ng, O.-T., Marimuthu, K., Ang, L. W., Mak, T. M., et al. (2020) · JAMA · doi:10.1001/jama.2020.3204 · Cited by 2,059
Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility
Arons, M. M., Hatfield, K. M., Reddy, S. C., Kimball, A., James, A., Jacobs, J. R., Taylor, J., Spicer, K., Bardossy, A. C., Oakley, L. P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2008457 · Cited by 2,052
Tian, H., Liu, Y., Li, Y., Wu, C.-H., Chen, B., Kraemer, M. U. G., Li, B., Cai, J., Xu, B., Yang, Q., et al. (2020) · Science · doi:10.1126/science.abb6105 · Cited by 2,010
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
Pan, L., Mu, M., Yang, P., Sun, Y., Wang, R., Yan, J., Li, P., Hu, B., Wang, J., Hu, C., et al. (2020) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000620 · Cited by 1,823
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
Structural and functional analysis of a potent sarbecovirus neutralizing antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · doi:10.1101/2020.04.07.023903 · Cited by 1,752
Coronavirus Main Proteinase (3CL pro ) Structure: Basis for Design of Anti-SARS Drugs
Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R., & Hilgenfeld, R. (2003) · Science · doi:10.1126/science.1085658 · Cited by 1,728
Viral dynamics in mild and severe cases of COVID-19
Liu, Y., Yan, L.-M., Wan, L., Xiang, T.-X., Le, A., Liu, J.-M., Peiris, M., Poon, L. L. M., & Zhang, W. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30232-2 · Cited by 1,727 · cited 1×
“A rigorous assessment of the diagnostic accuracy of the many newly introduced SARS-CoV-2 assays is hampered [37-38].”
MethodHuman neutralizing antibodies elicited by SARS-CoV-2 infection
Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Yu, J., Shan, S., Zhou, B., Song, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2380-z · Cited by 1,667 · cited 2×
“Indeed, antibodies to this protein are frequently detected in COVID-19 patient [64-65], suggesting that N protein may be one of the immunodominant antigens in the early diagnosis of COVID-19 [60, 66-67].”
BackgroundThe spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,661
Cheung, K. S., Hung, I. F. N., Chan, P. P. Y., Lung, K. C., Tso, E., Liu, R., Ng, Y. Y., Chu, M. Y., Chung, T. W. H., Tam, A. R., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.03.065 · Cited by 1,631 · cited 1×
“74 j 16 The virus was found in stool samples in around 50% of patients with COVID-19, with around 18% of them complaining of abdominal pain and diarrhoea.(99) It was demonstrated that SARS-CoV-2 is capable of productively replicating in ACE2-positive enterocytes.”
BackgroundCOVID-19: immunopathology and its implications for therapy
Cao, X. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0308-3 · Cited by 1,609
Structure of the RNA-dependent RNA polymerase from COVID-19 virus
Gao, Y., Yan, L., Huang, Y., Liu, F., Zhao, Y., Cao, L., Wang, T., Sun, Q., Ming, Z., Zhang, L., et al. (2020) · Science · doi:10.1126/science.abb7498 · Cited by 1,609
Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)
Guo, L., Ren, L., Yang, S., Xiao, M., Chang, D., Yang, F., Dela Cruz, C. S., Wang, Y., Wu, C., Xiao, Y., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa310 · Cited by 1,587
SARS-CoV-2 productively infects human gut enterocytes
Lamers, M. M., Beumer, J., van der Vaart, J., Knoops, K., Puschhof, J., Breugem, T. I., Ravelli, R. B. G., Paul van Schayck, J., Mykytyn, A. Z., Duimel, H. Q., et al. (2020) · Science · doi:10.1126/science.abc1669 · Cited by 1,573
Interpreting Diagnostic Tests for SARS-CoV-2
Sethuraman, N., Jeremiah, S. S., & Ryo, A. (2020) · JAMA · doi:10.1001/jama.2020.8259 · Cited by 1,494
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
Dai, W., Zhang, B., Jiang, X.-M., Su, H., Li, J., Zhao, Y., Xie, X., Jin, Z., Peng, J., Liu, F., et al. (2020) · Science · doi:10.1126/science.abb4489 · Cited by 1,478
Frequency and Distribution of Chest Radiographic Findings in Patients Positive for COVID-19
Wong, H. Y. F., Lam, H. Y. S., Fong, A. H.-T., Leung, S. T., Chin, T. W.-Y., Lo, C. S. Y., Lui, M. M.-S., Lee, J. C. Y., Chiu, K. W.-H., Chung, T. W.-H., et al. (2020) · Radiology · doi:10.1148/radiol.2020201160 · Cited by 1,477
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechsle, O., Phelan, A., Rawling, M., Savory, E., & Stebbing, J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30304-4 · Cited by 1,456
Hung, I. F.-N., Lung, K.-C., Tso, E. Y.-K., Liu, R., Chung, T. W.-H., Chu, M.-Y., Ng, Y.-Y., Lo, J., Chan, J., Tam, A. R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31042-4 · Cited by 1,455
Zheng, S., Fan, J., Yu, F., Feng, B., Lou, B., Zou, Q., Xie, G., Lin, S., Wang, R., Yang, X., et al. (2020) · BMJ · doi:10.1136/bmj.m1443 · Cited by 1,440
Kucirka, L. M., Lauer, S. A., Laeyendecker, O., Boon, D., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-1495 · Cited by 1,414
Jin, X., Lian, J.-S., Hu, J.-H., Gao, J., Zheng, L., Zhang, Y.-M., Hao, S.-R., Jia, H.-Y., Cai, H., Zhang, X.-L., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-320926 · Cited by 1,385
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Goldman, J. D., Lye, D. C. B., Hui, D. S., Marks, K. M., Bruno, R., Montejano, R., Spinner, C. D., Galli, M., Ahn, M.-Y., Nahass, R. G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2015301 · Cited by 1,362
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F.-W., Sahi, V., Figueroa, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2571-7 · Cited by 1,349
Laboratory Diagnosis of COVID-19: Current Issues and Challenges
Tang, Y.-W., Schmitz, J. E., Persing, D. H., & Stratton, C. W. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00512-20 · Cited by 1,232
Rogers, T. F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W.-T., Limbo, O., Smith, C., Song, G., Woehl, J., et al. (2020) · Science · doi:10.1126/science.abc7520 · Cited by 1,230
Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31605-6 · Cited by 1,225 · cited 4×
“early phase COVID-19 vaccine trials, one at Oxford University (UK), with support from AstraZeneca,(161) and the second supported by CanSino Biologics in China.(162) Both groups used an adenoviral vector, and both report the vaccine achieving humoral responses against the SARS-CoV-2 spike glycopro-”
ResultInfluentialVillar, J., Ferrando, C., Martínez, D., Ambrós, A., Muñoz, T., Soler, J. A., Aguilar, G., Alba, F., González-Higueras, E., Conesa, L. A., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30417-5 · Cited by 1,199
Sungnak, W., Huang, N., Bécavin, C., & Berg, M. (2020) · PubMed · Cited by 1,196
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19
Cortegiani, A., Ingoglia, G., Ippolito, M., Giarratano, A., & Einav, S. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.03.005 · Cited by 1,160
Pedersen, S. F., & Ho, Y.-C. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137647 · Cited by 1,137 · cited 1×
“It is now rather well established that in patients with poor outcome there is an uncontrolled “cytokine storm”, featuring a local and systemic production of pro-inflammatory cytokines such as IL-6, TNF-α and IL1β [23-27].”
BackgroundTang, W., Cao, Z., Han, M., Wang, Z., Chen, J., Sun, W., Wu, Y., Xiao, W., Liu, S., Chen, E., et al. (2020) · BMJ · doi:10.1136/bmj.m1849 · Cited by 1,135
Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy
George, P. M., Wells, A. U., & Jenkins, R. G. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30225-3 · Cited by 1,085
Mao, R., Qiu, Y., He, J.-S., Tan, J.-Y., Li, X.-H., Liang, J., Shen, J., Zhu, L.-R., Chen, Y., Iacucci, M., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30126-6 · Cited by 1,056
COVID-19: Abnormal liver function tests
Cai, Q., Huang, D., Yu, H., Zhu, Z., Xia, Z., Su, Y., Li, Z., Zhou, G., Gou, J., Qu, J., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.006 · Cited by 1,047
Potently neutralizing and protective human antibodies against SARS-CoV-2
Zost, S. J., Gilchuk, P., Case, J. B., Binshtein, E., Chen, R. E., Nkolola, J. P., Schäfer, A., Reidy, J. X., Trivette, A., Nargi, R. S., et al. (2020) · Nature · doi:10.1038/s41586-020-2548-6 · Cited by 1,041 · cited 1×
“viral spike protein is perceived as the clear candidate for inclusion in an immunoassay that detects whether antibodies are present.(58,63) The other protein that appears to be an important antigen for the development of serological assays is the N protein (structural component of the nucleocapsid).”
BackgroundRemdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
Choy, K.-T., Wong, A. Y.-L., Kaewpreedee, P., Sia, S. F., Chen, D., Hui, K. P. Y., Chu, D. K. W., Chan, M. C. W., Cheung, P. P.-H., Huang, X., et al. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104786 · Cited by 922
Humoral Immune Response to SARS-CoV-2 in Iceland
Gudbjartsson, D. F., Norddahl, G. L., Melsted, P., Gunnarsdottir, K., Holm, H., Eythorsson, E., Arnthorsson, A. O., Helgason, D., Bjarnadottir, K., Ingvarsson, R. F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2026116 · Cited by 903
Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors
Kirchdoerfer, R. N., & Ward, A. B. (2019) · Nature Communications · doi:10.1038/s41467-019-10280-3 · Cited by 896
Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT–qPCR primer–probe sets
Vogels, C. B. F., Brito, A. F., Wyllie, A. L., Fauver, J. R., Ott, I. M., Kalinich, C. C., Petrone, M. E., Casanovas-Massana, A., Catherine Muenker, M., Moore, A. J., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0761-6 · Cited by 876
Liver injury during highly pathogenic human coronavirus infections
Xu, L., Liu, J., Lu, M., Yang, D., & Zheng, X. (2020) · Liver International · doi:10.1111/liv.14435 · Cited by 852
Antibody tests for identification of current and past infection with SARS‐CoV‐2
Geppert, J., Scandrett, K., Bigio, J., Sulis, G., Hettiarachchi, D., Mathangasinghe, Y., Weeratunga, P., Wickramasinghe, D., Bergman, H., Buckley, S. B., et al. (2022) · LSTM Online Archive (Liverpool School of Tropical Medicine) · Cited by 850
Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission
Tian, Y., Rong, L., Nian, W., & He, Y. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15731 · Cited by 832
Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis
Lisboa Bastos, M., Tavaziva, G., Abidi, S. K., Campbell, J. R., Haraoui, L.-P., Johnston, J. C., Lan, Z., Law, S., MacLean, E., Trajman, A., et al. (2020) · BMJ · doi:10.1136/bmj.m2516 · Cited by 832
SARS-CoV-2 infection protects against rechallenge in rhesus macaques
Chandrashekar, A., Liu, J., Martinot, A. J., McMahan, K., Mercado, N. B., Peter, L., Tostanoski, L. H., Yu, J., Maliga, Z., Nekorchuk, M., et al. (2020) · Science · doi:10.1126/science.abc4776 · Cited by 816 · cited 1×
“Humoral and cell-mediated immune responses have been associated with vaccine-induced protection against challenge or subsequent re-challenge after SARSCoV-2 infection in a rhesus macaque model.(159) Long-term assessment will be relevant given that natural history studies suggest that SARS-CoV may not generate long-liv…”
BackgroundMassively multiplexed nucleic acid detection with Cas13
Ackerman, C. M., Myhrvold, C., Thakku, S. G., Freije, C. A., Metsky, H. C., Yang, D. K., Ye, S. H., Boehm, C. K., Kosoko-Thoroddsen, T.-S. F., Kehe, J., et al. (2020) · Nature · doi:10.1038/s41586-020-2279-8 · Cited by 803
False Negative Tests for SARS-CoV-2 Infection — Challenges and Implications
Woloshin, S., Patel, N., & Kesselheim, A. S. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2015897 · Cited by 803
To, K. K.-W., Hung, I. F.-N., Ip, J. D., Chu, A. W.-H., Chan, W.-M., Tam, A. R., Fong, C. H.-Y., Yuan, S., Tsoi, H.-W., Ng, A. C.-K., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1275 · Cited by 746
Essentials for Radiologists on COVID-19: An Update—Radiology Scientific Expert Panel
Kanne, J. P., Little, B. P., Chung, J. H., Elicker, B. M., & Ketai, L. H. (2020) · Radiology · doi:10.1148/radiol.2020200527 · Cited by 704
Dyall, J., Coleman, C. M., Hart, B. J., Venkataraman, T., Holbrook, M. R., Kindrachuk, J., Johnson, R. F., Olinger, G. G., Jahrling, P. B., Laidlaw, M., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03036-14 · Cited by 660
Antibody tests for identification of current and past infection with SARS-CoV-2
Deeks, J. J., Dinnes, J., Takwoingi, Y., Davenport, C., Spijker, R., Taylor-Phillips, S., Adriano, A., Beese, S., Dretzke, J., Ferrante di Ruffano, L., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013652 · Cited by 655
Diagnostic Testing for Severe Acute Respiratory Syndrome–Related Coronavirus 2: A Narrative Review
Cheng, M. P., Papenburg, J., Desjardins, M., Kanjilal, S., Quach, C., Libman, M., Dittrich, S., & Yansouni, C. P. (2020) · Annals of Internal Medicine · doi:10.7326/m20-1301 · Cited by 593
The emerging safety profile of JAK inhibitors in rheumatic disease
Winthrop, K. L. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.23 · Cited by 590
SARS — beginning to understand a new virus
Stadler, K., Masignani, V., Eickmann, M., Becker, S., Abrignani, S., Klenk, H.-D., & Rappuoli, R. (2003) · Nature Reviews Microbiology · doi:10.1038/nrmicro775 · Cited by 557
The laboratory tests and host immunity of COVID-19 patients with different severity of illness
Wang, F., Hou, H., Luo, Y., Tang, G., Wu, S., Huang, M., Liu, W., Zhu, Y., Lin, Q., Mao, L., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.137799 · Cited by 556
Acute kidney injury in critically ill patients with COVID-19
Gabarre, P., Dumas, G., Dupont, T., Darmon, M., Azoulay, E., & Zafrani, L. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06153-9 · Cited by 529
Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study
Ji, D., Qin, E., Xu, J., Zhang, D., Cheng, G., Wang, Y., & Lau, G. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.044 · Cited by 525
Self-citationThree Emerging Coronaviruses in Two Decades
Guarner, J. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaa029 · Cited by 503
Arbidol as a broad-spectrum antiviral: An update
Blaising, J., Polyak, S. J., & Pécheur, E.-I. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.04.006 · Cited by 485
Snijder, E. J., Limpens, R. W. A. L., de Wilde, A. H., de Jong, A. W. M., Zevenhoven-Dobbe, J. C., Maier, H. J., Faas, F. F. G. A., Koster, A. J., & Bárcena, M. (2020) · PLOS Biology · doi:10.1371/journal.pbio.3000715 · Cited by 477
Fix, O. K., Hameed, B., Fontana, R. J., Kwok, R. M., McGuire, B. M., Mulligan, D. C., Pratt, D. S., Russo, M. W., Schilsky, M. L., Verna, E. C., et al. (2020) · Hepatology · doi:10.1002/hep.31281 · Cited by 473
Chloroquine for the 2019 novel coronavirus SARS-CoV-2
Colson, P., Rolain, J.-M., & Raoult, D. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105923 · Cited by 468
Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques
Deng, W., Bao, L., Liu, J., Xiao, C., Liu, J., Xue, J., Lv, Q., Qi, F., Gao, H., Yu, P., et al. (2020) · Science · doi:10.1126/science.abc5343 · Cited by 440
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
Cantini, F., Niccoli, L., Matarrese, D., Nicastri, E., Stobbione, P., & Goletti, D. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.04.017 · Cited by 436
The stimulation of thrombosis by hypoxia
Gupta, N., Zhao, Y.-Y., & Evans, C. E. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.07.013 · Cited by 435
Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
Zhu, Z. H., Lu, Z., Xu, T., Chen, C., Yang, G., Zha, T. A., Lu, J., & Xue, Y. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.060 · Cited by 427
Park, G.-S., Ku, K., Baek, S.-H., Kim, S.-J., Kim, S. I., Kim, B.-T., & Maeng, J.-S. (2020) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2020.03.006 · Cited by 404
Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids
Zhao, B., Ni, C., Gao, R., Wang, Y., Yang, L., Wei, J., Lv, T., Liang, J., Zhang, Q., Xu, W., et al. (2020) · Protein & Cell · doi:10.1007/s13238-020-00718-6 · Cited by 399
COVID-19 diagnostics in context
Weissleder, R., Lee, H., Ko, J., & Pittet, M. J. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abc1931 · Cited by 396
Disappearance of Antibodies to SARS-Associated Coronavirus after Recovery
Cao, W.-C., Liu, W., Zhang, P.-H., Zhang, F., & Richardus, J. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070348 · Cited by 367
An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment
GeurtsvanKessel, C. H., Okba, N. M. A., Igloi, Z., Bogers, S., Embregts, C. W. E., Laksono, B. M., Leijten, L., Rokx, C., Rijnders, B., Rahamat-Langendoen, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17317-y · Cited by 361 · cited 1×
“dently validated, and used as part of an algorithm to achieve the highest possible accuracy for decision making.(74,75) Second, there is insufficient data on the magnitude and duration of antibody responses after infections.”
MethodSaliva as a Noninvasive Specimen for Detection of SARS-CoV-2
Williams, E., Bond, K., Zhang, B., Putland, M., & Williamson, D. A. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00776-20 · Cited by 361
Developing antibody tests for SARS-CoV-2
Petherick, A. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30788-1 · Cited by 359
Secondary attack rate and superspreading events for SARS-CoV-2
Liu, Y., Eggo, R. M., & Kucharski, A. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30462-1 · Cited by 350 · cited 2×
“Indeed, antibodies to this protein are frequently detected in COVID-19 patient [64-65], suggesting that N protein may be one of the immunodominant antigens in the early diagnosis of COVID-19 [60, 66-67].”
BackgroundPre-existing immunity to SARS-CoV-2: the knowns and unknowns
Sette, A., & Crotty, S. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0389-z · Cited by 347
Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with Pneumonia, China
Wu, X., Cai, Y., Huang, X., Yu, X., Zhao, L., Wang, F., Li, Q., Gu, S., Xu, T., Li, Y., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2606.200299 · Cited by 330
Sample Pooling as a Strategy to Detect Community Transmission of SARS-CoV-2
Hogan, C. A., Sahoo, M. K., & Pinsky, B. A. (2020) · JAMA · doi:10.1001/jama.2020.5445 · Cited by 312
Drug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 Therapeutics
Ghosh, A. K., Brindisi, M., Shahabi, D., Chapman, M. E., & Mesecar, A. D. (2020) · ChemMedChem · doi:10.1002/cmdc.202000223 · Cited by 306 · cited 3×
“Moreover biochemical assays are also available for functional testing, at least for the SARS-CoV proteins.(20) PLpro is a cysteine protease, encoded by Nsp3, and involved in the release of Nsp1 to 3, as well as in the regulation of host innate immunity, enabling viral escape.”
BackgroundMethodInfluentialMechanism of baricitinib supports artificial intelligence‐predicted testing in COVID ‐19 patients
Stebbing, J., Krishnan, V., de Bono, S., Ottaviani, S., Casalini, G., Richardson, P. J., Monteil, V., Lauschke, V. M., Mirazimi, A., Youhanna, S., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012697 · Cited by 291
COVID-19 and neuromuscular disorders
Guidon, A. C., & Amato, A. A. (2020) · Neurology · doi:10.1212/wnl.0000000000009566 · Cited by 275
Freedberg, D. E., Conigliaro, J., Wang, T. C., Tracey, K. J., Callahan, M. V., Abrams, J. A., Sobieszczyk, M. E., Markowitz, D. D., Gupta, A., O’Donnell, M. R., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.05.053 · Cited by 257
An ALOX12–12-HETE–GPR31 signaling axis is a key mediator of hepatic ischemia–reperfusion injury
Zhang, X.-J., Cheng, X., Yan, Z.-Z., Fang, J., Wang, X., Wang, W., Liu, Z.-Y., Shen, L.-J., Zhang, P., Wang, P.-X., et al. (2018) · Nature Medicine · doi:10.1038/nm.4451 · Cited by 239
Cutaneous signs in COVID ‐19 patients: A review
Wollina, U., Karadağ, A. S., Rowland‐Payne, C., Chiriac, A., & Lotti, T. (2020) · Dermatologic Therapy · doi:10.1111/dth.13549 · Cited by 231
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
La Rosée, F., Bremer, H. C., Gehrke, I., Kehr, A., Hochhaus, A., Birndt, S., Fellhauer, M., Henkes, M., Kumle, B., Russo, S. G., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0891-0 · Cited by 231
Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges
Baumert, T. F., Berg, T., Lim, J. K., & Nelson, D. R. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.10.024 · Cited by 184
Magrone, T., Magrone, M., & Jirillo, E. (2020) · Endocrine, Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200427112902 · Cited by 183
The Promise and Peril of Antibody Testing for COVID-19
Abbasi, J. (2020) · JAMA · doi:10.1001/jama.2020.6170 · Cited by 181
How to Obtain a Nasopharyngeal Swab Specimen
(2020) · New England Journal of Medicine · doi:10.1056/nejmc2015949 · Cited by 179
Ten reasons why immunity passports are a bad idea
Kofler, N., & Baylis, F. (2020) · Nature · doi:10.1038/d41586-020-01451-0 · Cited by 169
Zhou, Y., Zheng, K. I., Wang, X., Yan, H.-D., Sun, Q., Pan, K.-H., Wang, T.-Y., Ma, H., Chen, Y.-P., George, J., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.027 · Cited by 138
Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019
Titanji, B. K., Farley, M. M., Mehta, A., Connor‐Schuler, R., Moanna, A., Cribbs, S. K., O’Shea, J., DeSilva, K. E., Chan, B., Edwards, A., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa879 · Cited by 131
Self-citationCOVID-19 and drug-induced liver injury: a problem of plenty or a petty point?
Boeckmans, J., Rodrigues, R. M., Demuyser, T., Piérard, D., Vanhaecke, T., & Rogiers, V. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02734-1 · Cited by 129
Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors
Gavegnano, C., Brehm, J. H., Dupuy, F. P., Talla, A., Ribeiro, S. P., Kulpa, D. A., Cameron, C., Santos, S., Hurwitz, S. J., Marconi, V. C., et al. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006740 · Cited by 115
Self-citationGavegnano, C., Detorio, M., Montero, C. M., Bosque, A., Planelles, V., & Schinazi, R. F. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02496-13 · Cited by 110
Self-citationAPASL Covid-19 Task Force, Lau, G., & Sharma, M. (2020) · Hepatology International · doi:10.1007/s12072-020-10054-w · Cited by 88 · cited 2×
“Prophylactic nucleoside analogs against hepatitis B virus had been recommended for those hepatitis B surface antigen positive COVID-19 patients planned for immunosuppressive therapy [102].”
BackgroundSelf-citationCortegiani, A., Ippolito, M., Ingoglia, G., Iozzo, P., Giarratano, A., & Einav, S. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.06.019 · Cited by 81
Effect of COVID-19 on patients with compensated chronic liver diseases
Ji, D., Zhang, D., Yang, T., Mu, J., Zhao, P., Xu, J., Li, C., Cheng, G. Y.-M., Wang, Y., Zhu, C., et al. (2020) · Hepatology International · doi:10.1007/s12072-020-10058-6 · Cited by 73
Self-citationGavegnano, C., Haile, W. B., Hurwitz, S. J., Tao, S., Jiang, Y., Schinazi, R. F., & Tyor, W. R. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1565-6 · Cited by 72
Self-citationMusumeci, F., Greco, C., Giacchello, I., Fallacara, A. L., Ibrahim, M. M., Grossi, G., Brullo, C., & Schenone, S. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180327093502 · Cited by 46
Lau, G. K. K., & Ward, J. W. (2020) · Clinical Liver Disease · doi:10.1002/cld.972 · Cited by 37
Self-citationVastag, B. (2003) · JAMA · doi:10.1001/jama.290.13.1695 · Cited by 34
Cited by
Bai, Z., Cao, Y., Liu, W., & Li, J. (2021) · Viruses · doi:10.3390/v13061115 · Cited by 348
Recent advances in regenerative biomaterials
Cao, D., & Ding, J. (2022) · Regenerative Biomaterials · doi:10.1093/rb/rbac098 · Cited by 259
Dhakal, A., McKay, C., Tanner, J. J., & Cheng, J. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbab476 · Cited by 256
Metadata
- Authors
- Asselah, T., Durantel, D., Pasmant, E., Lau, G., & Schinazi, R. F.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 74
- Issue
- 1
- Pages
- 168-184
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W3091999679
- Cited by
- 437
- References
- 154
- FWCI
- 10.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.